Weight-Loss Drugs May Raise Hair-Loss Risk In Men Genetically Prone To Baldness

Weight-loss injections that have become increasingly popular for shedding kilos may have an unexpected downside for some men — hair loss.

A new genetic study has found a link between GLP-1 activity and male-pattern baldness, particularly in men already genetically predisposed to hair loss.

This comes amid the growing popularity of drugs such as Ozempic, Wegovy and Mounjaro, which are increasingly being used not just for medically indicated obesity and diabetes treatment but also as quick-fix slimming solutions.

Dermatologists too said the problem is no longer simply whether these medicines work for weight loss, but whether people are using them responsibly and with adequate nutritional and medical monitoring.

The study by researchers from NYU Langone Health, published in the Journal of Investigative Dermatology, found that men with a genetic predisposition to androgenetic alopecia had an additional 7% risk of hair loss associated with GLP-1 activity.

The researchers adjusted their analysis for factors including high blood pressure, insulin resistance and low testosterone, and the association persisted.

Importantly, researchers have not established that GLP-1 medicines directly cause permanent baldness. The study also does not suggest that patients should stop prescribed treatment. Rather, it points to a possible biological link that needs further investigation and could eventually help doctors identify people who are more vulnerable to hair loss before starting treatment.

For dermatologists, however, the emerging issue is broader than the genetic finding.

Dr Gaurav Garg, Senior Dermatologist, Hair Transplant Surgeon, Dermato-Surgeon and Medical Director, Dermalife Skin and Hair Clinic, Delhi, said a substantial number of patients visiting his clinic after using GLP-1 medicines complain of hair shedding.

“We are seeing a significant rise in patients complaining of excessive hair shedding after taking GLP-1 weight loss medications. Around 40% of the weight loss drug users visiting our clinics are experiencing mild to significant hair loss,” he said.

Rapid weight loss can put the body under physical and metabolic stress, pushing more hair follicles into a resting phase. Hair shedding may then become noticeable weeks or even months after the weight loss, said Dr Garg.

This temporary shedding is commonly referred to as “Ozempic Hair”, although it is not a formal medical diagnosis. Doctors generally classify it as telogen effluvium, a form of hair loss that can occur after physical or metabolic stress.

Nutrition too can add to the problem. GLP-1 medicines suppress appetite, and some people may end up eating much less. If the diet does not provide enough protein, iron, zinc and other essential nutrients, hair growth can be affected.

For Dr Garg, the bigger concern is the growing perception of weight-loss injections as cosmetic quick fixes.

“One of the biggest concerns today is that these weight loss injections are increasingly being viewed as quick-fix cosmetic solutions rather than prescription medicines meant for specific medical conditions,” Dr Garg said.

He said some people start the medicines after seeing social media content or following advice from friends, without understanding the nutritional consequences of rapid weight loss. He stressed the importance of dietary counselling, adequate protein intake and regular monitoring during medical weight management.

On the other hand, Dr Rashmi Sarkar, Director-Professor and Head, Department of Dermatology, VMMC and Safdarjung Hospital, Delhi, said “Ozempic hair” was often less about the drug directly damaging hair follicles and more about the physiological stress caused by rapid weight loss.

“When calorie and protein intake fall sharply, hair follicles can shift into a resting phase, and significant shedding may follow. The message should not be to fear these medicines, but to use them responsibly—with medical supervision, adequate nutrition and a sensible pace of weight loss.”

Dr Sakshi Gagneja, Consultant-Endocrinology, Apollomedics Hospitals, Lucknow, said hair thinning and increased shedding had emerged as concerns among some users of weight-loss drugs.

“Semaglutide, commonly known by brand names such as Ozempic and Wegovy, along with other weight-loss medications such as tirzepatide and many more, has gained significant popularity among people looking to manage obesity and lose weight."

“However, hair thinning or increased hair shedding has emerged as a concern among some users. Recent research has suggested a possible association between GLP-1 medications and hair loss, although the evidence is still evolving, and it is too early to conclude that these medicines directly cause permanent hair loss.”

She said the shedding seen in many cases could be linked to the speed and extent of weight loss rather than a direct effect of the medication on hair follicles. A sudden drop in calorie intake, body weight or essential nutrients can push a larger number of follicles into the resting phase of the hair-growth cycle. The resulting condition, known as telogen effluvium, can cause noticeable shedding several weeks or months after the weight loss.

For Dr Ramanjeet Singh, Director, Department of Dermatology, Medanta Hospital, the growing use of the term “Ozempic Hair” highlighted concerns over the unsupervised use of weight-loss medicines.

“The emerging trend of 'Ozempic Hair' highlights the risks associated not only with rapid weight loss but also with the indiscriminate use of these medications without proper medical evaluation,” he said.

Hence, for people using these medicines, doctors said, the focus should be on safe and supervised weight management rather than rapid weight loss. They advised against self-medication or increasing doses without medical advice and stressed the importance of adequate protein and balanced nutrition. Any documented iron, vitamin or other nutritional deficiencies should also be addressed. Persistent or excessive hair shedding should prompt medical evaluation rather than abrupt discontinuation of the weight-loss medicine.